Patents by Inventor Matthias Staufenbiel

Matthias Staufenbiel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150374807
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune, responses within the indicated context.
    Type: Application
    Filed: July 1, 2015
    Publication date: December 31, 2015
    Applicant: Novartis AG
    Inventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Martin Lueoend, Matthias Staufenbiel, Peter Frey
  • Publication number: 20150202281
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: May 30, 2013
    Publication date: July 23, 2015
    Applicants: CYTOS BIOTECHNOLOGY AG, NOVARTIS PHARMA AG
    Inventors: Wolfgang A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey
  • Publication number: 20140294876
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
    Type: Application
    Filed: December 13, 2013
    Publication date: October 2, 2014
    Applicant: NOVARTIS AG
    Inventors: Martin F. BACHMANN, Alain TISSOT, Rainer ORTMANN, Rainer LUEOEND, Matthias STAUFENBIEL, Peter FREY
  • Publication number: 20140079730
    Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 20, 2014
    Applicant: NOVARTIS AG
    Inventors: Ana GRAF, Matthias STAUFENBIEL, Thomas BLÄTTLER, Paolo PAGANETTI
  • Patent number: 8617566
    Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A beta-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: December 31, 2013
    Assignee: Novartis AG
    Inventors: Ana Graf, Matthias Staufenbiel, Thomas Blaettler, Paolo Paganetti
  • Publication number: 20130252889
    Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the AD-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia.
    Type: Application
    Filed: May 13, 2013
    Publication date: September 26, 2013
    Applicant: Novartis AG
    Inventors: Ana GRAF, Matthias STAUFENBIEL, Thomas BLÄTTLER, Paolo PAGANETTI
  • Patent number: 8460676
    Abstract: The present invention relates to uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: June 11, 2013
    Assignee: Novartis AG
    Inventors: Ana Graf, Matthias Staufenbiel, Thomas Blättler, Paolo Paganetti
  • Publication number: 20120114674
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 10, 2012
    Applicants: NOVARTIS PHARMA AG, CYTOS BIOTECHNOLOGY AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey
  • Publication number: 20110086036
    Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the A
    Type: Application
    Filed: December 17, 2010
    Publication date: April 14, 2011
    Inventors: Ana Graf, Matthias Staufenbiel, Thomas Blättler, Paolo Paganetti
  • Patent number: 7867499
    Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: January 11, 2011
    Assignee: Novartis AG
    Inventors: Ana Graf, Matthias Staufenbiel, Thomas Blättler, Paolo Paganetti
  • Publication number: 20090246215
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
    Type: Application
    Filed: October 5, 2007
    Publication date: October 1, 2009
    Inventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
  • Publication number: 20090060899
    Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the A
    Type: Application
    Filed: November 3, 2005
    Publication date: March 5, 2009
    Inventors: Ana Graf, Matthias Staufenbiel, Thomas Blattler, Paolo Paganetti
  • Publication number: 20080274131
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: January 18, 2008
    Publication date: November 6, 2008
    Applicants: Cytos Biotechnology AG, Novartis Pharma AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
  • Patent number: 7320793
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: January 22, 2008
    Assignees: Cytos Biotechnology AG, Novartis Pharma AG
    Inventors: Wolfgang A Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
  • Patent number: 7279165
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: October 9, 2007
    Assignee: Cytos Biotechnology AG
    Inventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Lūönd, Matthias Staufenbiel, Peter Frey
  • Publication number: 20070142401
    Abstract: The invention relates to the use of an inhibitor of formula (I), or a pharmaceutically acceptable salt thereof having an activity on protein kinases PKC alpha, PKC beta, PKC gamma, PKC epsilon, PKC theta, CDK-1, KDR, PKA, Flt-1, Flt-2, Flt-3 or Flt-4, or on a combination of the above enzymes, for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.
    Type: Application
    Filed: October 26, 2004
    Publication date: June 21, 2007
    Applicant: NOVARTIS AG
    Inventors: Yves Auberson, Graeme Bilbe, Rainer Kuhn, Peter Von Matt, Heinrich Rueger, Matthias Staufenbiel, Jurgen Wagner, Kaspar Zimmermann
  • Publication number: 20040141984
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A&bgr;1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A&bgr;1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
    Type: Application
    Filed: July 18, 2003
    Publication date: July 22, 2004
    Applicants: Cytos Biotechnology AG, Novartis Pharma AG
    Inventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
  • Publication number: 20030175711
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: January 18, 2002
    Publication date: September 18, 2003
    Applicant: Cytos Biotechnology AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
  • Publication number: 20030101467
    Abstract: Animal model involving transgenic manipulation of amyloid precursor protein, useful for testing potential therapeutic agents for the treatment of neurodegenerative disorders, in particular Alzheimer's disease.
    Type: Application
    Filed: January 2, 2003
    Publication date: May 29, 2003
    Inventors: Bernd Sommer, Matthias Staufenbiel
  • Publication number: 20010016951
    Abstract: Animal model involving transgenic manipulation of amyloid precursor protein, useful for testing potential therapeutic agents for the treatment of neurodegenerative disorders, in particular Alzheimer's disease.
    Type: Application
    Filed: April 25, 2001
    Publication date: August 23, 2001
    Inventors: Bernd Sommer, Matthias Staufenbiel